drugset / Trial / NCT00698035

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

NCT00698035

Phase 2 Completed 76 enrolled University of California, San Francisco
RandomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients. This study will also evaluate if either of these treatments can improve symptoms of vaginal dryness or decreased sexual interest that are related to your treatment for breast cancer.

Timeline

Start
2007-03
Primary completion
2012-10
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 2 mg Other
Comparator Testosterone Cream Unknown 0.5 g Other